Outcome MeasureSafety / Adverse Events

BSS

Beck Scale for Suicidal Ideation

6 Papers in Blossom

Outcome Data Across Studies

Reported results for BSS across 6 studies with quantitative data.

Outcome data across 22 study arm–timepoint observations
SD
Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study
2021Primary
Oral ketamine(experimental)03220.04.7—
Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study
2021Primary
Oral ketamine(experimental)42325.67.6—
Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study
2021Primary
Oral ketamine(experimental)70309.18.2—
Relationships between reduction in symptoms and restoration of function and wellbeing: Outcomes of the Oral Ketamine Trial on Suicidality (OKTOS)
2021Secondary
Oral ketamine(experimental)03219.5——
Relationships between reduction in symptoms and restoration of function and wellbeing: Outcomes of the Oral Ketamine Trial on Suicidality (OKTOS)
2021Secondary
Oral ketamine(experimental)703010.0——
Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial
2021Primary
Intranasal Ketamine(experimental)01525.65.2—
Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial
2021Primary
Intranasal Saline Placebo(inactive)01523.84.8—
Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial
2021Primary
Intranasal Ketamine(experimental)0.167158.2—0.086
Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial
2021Primary
Intranasal Saline Placebo(inactive)0.1671513.3—0.086
Cognitive Function Mediates the Anti-suicide Effect of Repeated Intravenous Ketamine in Adult Patients With Suicidal Ideation
2022Primary
Repeated ketamine infusions(experimental)0864.73.0—

Papers Using BSS

Paywallindividual

Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression

This open-label fixed-order dose-escalation trial (n=14) evaluated inhaled DMT (15mg & 60mg) for treatment-resistant depression (TRD) for the first time. Results showed rapid and sustained antidepressant effects with a 21-point reduction on the Montgomery-Asberg Depression Rating Scale by day 7 (p<0.001), an 86% response rate, and a 57% remission rate lasting up to 3 months, with significant decreases in suicidal ideation (SI).

Published
Journal
Neuropsychopharmacology
Authors
Falchi-Carvalho, M., Palhano-Fontes, F., Wießner, I., Barros, H., Bolcont, R., Laborde, S., Silva, S. R. B., Montanini, D., Barbosa, D. C., Teixeira, E., Florence-Vilela, R., Almeida, R., Macedo, R. K. A., Arichelle, F., Pantrigo, E. J., Costa-Macedo, J. V., da Cruz Nunes, J. A., Araújo, D. B., de Araujo Costa Neto, L. A., Nunes Ferreira, L. F., Dantas Correa, L., da Costa Bezerra, R. B., Arcoverde, E., Galvão-Coelho, N. L.
Open Accessindividual

Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems

In a double-blind, randomised pilot study of 28 people with alcohol problems, sublingual esketamine (115.1 mg) combined with two weeks of daily mindfulness-based intervention increased psychological engagement with the practice and produced transient reductions in alcohol craving versus placebo. Esketamine also elicited greater mystical and dissociative experiences, suggesting these altered states may underlie enhanced engagement and potential therapeutic benefit.

Published
Journal
Journal of Psychopharmacology
Authors
Gent, E. M., Bryan, J. W., Cleary, M. A., Clarke, T. I., Holmwood, H. D., Nassereddine, R. O., Salway, C., Depla, S., Statton, S., Krecké, J., Morgan, C. J.
Open Accessindividual

Cognitive Function Mediates the Anti-suicide Effect of Repeated Intravenous Ketamine in Adult Patients With Suicidal Ideation

In adults with unipolar or bipolar depression and suicidal ideation, six intravenous ketamine infusions over two weeks produced significant reductions in suicidal ideation. Mediation analyses showed these anti‑suicide effects were partially mediated by reductions in depressive symptom severity and by improved processing speed, but not by other cognitive domains.

Published
Journal
Frontiers in Psychiatry
Authors
Zhou, Y-L., Wang, C., Lan, X-F., Chao, Z., McIntyre, R. S., Ning, Y-P., Wu, K.
Paywallindividual

Relationships between reduction in symptoms and restoration of function and wellbeing: Outcomes of the Oral Ketamine Trial on Suicidality (OKTOS)

This open-label trial (n=30) examined the effects of weekly oral ketamine treatment over six weeks on functional recovery in adults with chronic suicidality. It finds that while depression and suicidality scores improved, effect sizes for social functioning and wellbeing were smaller, suggesting that symptom reduction alone may not restore full functioning.

Published
Journal
Psychiatry Research
Authors
Beaudequin, D. A., Can, A. T., Jones, M., Yang, C., Scherman, J., Dutton, M., Schwenn, P. E., Forsyth, C. G., Jensen, E., Hermens, D. F., Lagopoulos, J.
Open Accessindividual

Single, Fixed-Dose Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial

This double-blind placebo-controlled study study (n=30) with intranasal ketamine (40mg) found significant reductions in suicidal ideation (SI, 80 vs 33% remission) and depressive symptoms (MADRS) 4 hours after administration for those with SI in the emergency department.

Published
Journal
Archives of Suicide Research
Authors
Domany, Y., McCullumsmith, C. B.
Open Accessindividual

Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study

In an open‑label pilot (n = 32) of six weeks' low‑dose oral ketamine for chronic suicidality, mean Beck Scale for Suicide Ideation scores fell from above to below the clinical threshold, with 69% showing clinical improvement at week 6 and 50% maintaining significant improvement at 10‑week follow‑up. These results suggest oral ketamine is a feasible, tolerable alternative to IV ketamine for reducing suicidal ideation.

Published
Journal
Translational Psychiatry
Authors
Can, A. T., Hermens, D. F., Dutton, M., Gallay, C. C., Jensen, E., Jones, M., Scherman, J., Beaudequin, D. A., Yang, C., Schwenn, P. E., Lagopoulos, J.

Quick Facts

Full Name
Beck Scale for Suicidal Ideation
Domain
Safety / Adverse Events
Papers Indexed
6
Score Range
0–38
Interpretation
Lower = better
Unit
points
All Measures